The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson disease severity.

A small study of Sanofi’s lixisenatide has suggested that the GLP-1 agonist could slow down the progression of Parkinson’s disease, pointing to another potential use for the fast-growing drug ...

An obesity medicine physician writes that weight-loss drugs such as Ozempic have been getting a bad rap, almost as if those ...

Sure, who wouldn’t want to lose a few pounds? But what’s really driving Hollywood’s latest trend is the drug’s seemingly miraculous side benefits ...

The active ingredient in Ozempic and Wegovy was linked to reduced cravings for drinking alcohol among people with alcohol use ...

Q1 2025 Earnings Call Transcript February 10, 2025 Arrowhead Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-1.39 EPS, expectations were $-0.42. Chris Anzalone: Thanks, Vince.

These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new ...

As demand remains high for GLP-1 drugs, primary care physicians are concerned about the risks of patients using third-party ...

A game-changer for obesity and heart failure? Dr Pandey reveals breakthrough GLP-1 trial results that show reduced cardiovascular risk and better outcomes for HFpEF patients. Don’t miss this!

Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan. 1 to some medical conditions, but not obesity or weight loss.